2024
Thirty-Day Outcomes from the Disrupt PAD BTK II Study of the Shockwave Intravascular Lithotripsy System for Treatment of Calcified Below-the-Knee Peripheral Arterial Disease
Chandra V, Lansky A, Sayfo S, Shammas N, Soukas P, Park J, Siah M, Babaev A, Shields R, West N, Armstrong E. Thirty-Day Outcomes from the Disrupt PAD BTK II Study of the Shockwave Intravascular Lithotripsy System for Treatment of Calcified Below-the-Knee Peripheral Arterial Disease. Journal Of Vascular Surgery 2024 PMID: 39536842, DOI: 10.1016/j.jvs.2024.11.003.Peer-Reviewed Original ResearchPost-operative deathsII studyPercutaneous transluminal angioplastyProcedural successBTK lesionsResidual stenosisFollow-upIntravascular lithotripsyIndex limbCore labRutherford category 3Treated target lesionsUltrasound core laboratoryInterventional clinical studyAngiographic core labThirty-day outcomesMinimal adverse eventsTarget lesion lengthSevere lesion calcificationIVL systemAdverse limb eventsOptimal standard of careStandard of carePeripheral arterial diseaseVascuQol scores
2013
Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial.
Caixeta A, Lansky AJ, Mehran R, Brener SJ, Claessen B, Généreux P, Palmerini T, Witzenbichler B, Guagliumi G, Brodie BR, Dudek D, Fahy M, Dangas GD, Stone GW. Predictors of suboptimal TIMI flow after primary angioplasty for acute myocardial infarction: results from the HORIZONS-AMI trial. EuroIntervention 2013, 9: 220-7. PMID: 23518872, DOI: 10.4244/eijv9i2a37.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAngioplasty, Balloon, CoronaryAntithrombinsChi-Square DistributionCoronary AngiographyCoronary CirculationFemaleHumansKaplan-Meier EstimateLogistic ModelsMaleMiddle AgedMyocardial InfarctionOdds RatioPlatelet Aggregation InhibitorsPredictive Value of TestsProportional Hazards ModelsProspective StudiesRecovery of FunctionRisk FactorsTime FactorsTreatment OutcomeConceptsTIMI 3 flowFinal TIMI 3 flowHORIZONS-AMI trialAcute myocardial infarctionPrimary PCITIMI flowMyocardial infarctionGlycoprotein IIb/IIIa inhibitorsIIb/IIIa inhibitorsNormal TIMI flowThree-year mortalityMulticentre prospective studyPatient-related factorsBaseline TIMIAngiographic factorsPrimary angioplastyIndependent predictorsUnfractionated heparinProspective studyAnterior MIAnatomical factorsPatientsTIMICore labLesion length
2009
Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction
RABBANI LE, IYENGAR S, DANGAS GD, GRINES CL, COX DA, GARCIA E, TCHENG JE, GRIFFIN JJ, GUAGLIUMI G, STUCKEY T, TURCO M, STANT J, FAHY M, LANSKY AJ, MEHRAN R, STONE GW. Impact of Thienopyridine Administration Prior to Primary Stenting in Acute Myocardial Infarction. Journal Of Interventional Cardiology 2009, 22: 378-384. PMID: 19496901, DOI: 10.1111/j.1540-8183.2009.00474.x.Peer-Reviewed Original ResearchMeSH KeywordsAbciximabAgedAngioplasty, Balloon, CoronaryAntibodies, MonoclonalAspirinConfidence IntervalsDrug Therapy, CombinationDrug-Eluting StentsFemaleHumansImmunoglobulin Fab FragmentsKaplan-Meier EstimateMaleMiddle AgedMultivariate AnalysisMyocardial InfarctionMyocardial RevascularizationOdds RatioPlatelet Aggregation InhibitorsPreoperative CarePyridinesTime FactorsConceptsMajor adverse cardiovascular eventsAcute myocardial infarctionTarget vessel revascularizationIschemic target vessel revascularizationPrimary stentingThienopyridine administrationLoading doseTH patientsStent implantationMyocardial infarctionClopidogrel loading doseAdverse cardiovascular eventsSuperior clinical outcomesBare-metal stentingAbciximab useCADILLAC trialCardiovascular eventsVessel revascularizationClinical outcomesMetal stentingProcedural characteristicsOperator's discretionPatientsStentingCore lab